Clinical Trials Logo

Clinical Trial Summary

Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15 persons per million. Although current therapy has improve disease prognosis, PAH still has a poor survival, with a median survival of 2.8 years after diagnosis. In the last few years new key elements in PAH pathogenesis have been discovered, such as the role of metabolism in disease onset and progression. In fact, PAH pulmonary smooth muscle cells switch into a glycolytic phenotype which resembles the metabolism of cancer cells. The investigators hypothesis is that "fatty acid oxidation inhibition reverts the PAH adverse phenotype by restoring mitochondrial function and morphology, decreasing proliferation and restoring apoptosis susceptibility in pulmonary smooth muscle cells "


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02102672
Study type Interventional
Source Pontificia Universidad Catolica de Chile
Contact Pablo F Castro, MD
Phone +56223543334
Email pcastro@med.puc.cl
Status Recruiting
Phase Phase 2
Start date March 2014
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT05056532 - Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Active, not recruiting NCT06003244 - High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT) N/A
Active, not recruiting NCT06072417 - HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level) N/A
Recruiting NCT02966665 - : Vascular Function in Health and Disease Phase 1
Recruiting NCT00502398 - Is There Intravascular Hemolysis in Patients With Pulmonary Hypertension? N/A
Completed NCT04456998 - GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) Phase 2
Not yet recruiting NCT06035861 - Endothelial Cell Activation and Total Pulmonary Resistance in PAH N/A
Recruiting NCT03138863 - Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO) N/A
Withdrawn NCT06122922 - Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) Phase 2
Recruiting NCT03195543 - Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
Completed NCT04337671 - Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension N/A
Completed NCT03198910 - Retrospective Data Analysis of Data From the Zurich PH Registry
Completed NCT03979482 - Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Active, not recruiting NCT05996302 - HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level) N/A
Active, not recruiting NCT06084559 - HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT) N/A
Withdrawn NCT02684786 - A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension Phase 1
Not yet recruiting NCT06258850 - REstoration of VItamin D in Pulmonary Arterial Hypertension Phase 4
Completed NCT04094272 - Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection
Active, not recruiting NCT01763112 - Training With Whole Body Vibration Device in Patients With PAH N/A
Completed NCT01581086 - Vascular Subphenotypes of Lung Disease in HIV & COPD N/A